Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly's experimental GLP-1 pill, orforglipron, demonstrated significant weight loss benefits in overweight adults with ...

Eli Lilly (LLY) stock soars as its weight loss therapy advances in trials. Learn how top pharma stocks compare, backed by ...

Eli Lilly has announced to go for global approval by the end of 2015 after completing the successful trials. The once-daily ...

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.

Eli Lilly (LLY) stock is up as the firm's oral weight loss drug orforglipron hits key goals in another Phase 3 trial, ...

Eli Lilly stated that results from a late-stage trial of its pill variant of GLP-1 drugs met the requirements for global ...

Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose ...